Jonathan Symonds Buys 1,500 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK) insider Jonathan Symonds acquired 1,500 shares of GSK stock in a transaction that occurred on Friday, December 20th. The shares were purchased at an average price of GBX 1,315 ($16.53) per share, for a total transaction of £19,725 ($24,792.61).

Jonathan Symonds also recently made the following trade(s):

• On Wednesday, October 30th, Jonathan Symonds bought 7,150 shares of GSK stock. The stock was purchased at an average price of GBX 1,394 ($17.52) per share, with a total value of £99,671 ($125,277.78).

GSK Trading Up 1.9 %

Shares of LON GSK traded up GBX 25.50 ($0.32) during midday trading on Monday, reaching GBX 1,334 ($16.77). The stock had a trading volume of 3,698,402 shares, compared to its average volume of 9,962,725. The company’s 50 day moving average price is GBX 1,387.25 and its 200 day moving average price is GBX 1,507.27. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. GSK plc has a twelve month low of GBX 1,282.50 ($16.12) and a twelve month high of GBX 1,823.50 ($22.92). The firm has a market cap of £54.43 billion, a price-to-earnings ratio of 1,180.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK Announces Dividend

The company also recently announced a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be issued a GBX 15 ($0.19) dividend. The ex-dividend date is Thursday, November 14th. This represents a yield of 1.03%. GSK’s payout ratio is 5,309.73%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on GSK shares. Berenberg Bank lowered their price objective on GSK from GBX 1,820 ($22.88) to GBX 1,600 ($20.11) and set a “buy” rating for the company in a research note on Friday, November 29th. Shore Capital restated a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Wednesday, December 11th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,850 ($23.25) price objective on shares of GSK in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.70).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.